Vortex Biosciences announces Dr. Adrian Kinkaid as new CEO
London, UK 2nd June 2021 (PR WEB) EMV Capital portfolio company, Vortex Biosciences, the cancer diagnosis biotechnology business, has announced … Read more
London, UK 2nd June 2021 (PR WEB) EMV Capital portfolio company, Vortex Biosciences, the cancer diagnosis biotechnology business, has announced … Read more
[LONDON, UK] London-based Q-Bot, an EMVC portfolio robotics company that has developed a solution to remotely apply underfloor insulation, has … Read more
What Investment features EMV Capital’s Ilian Iliev’s Article on Smart Cities as a Global opportunity – highlighting some of the … Read more
What exactly is a smart city? In the last decade, the traditional city has undergone a dramatic shift into becoming … Read more
Disclaimer Investing in start-ups and early-stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution. It should be done only as part of a diversified portfolio. Any investments are targeted exclusively at investors who understand the risks of investing in early-stage businesses and can make their own investment decisions. Any pitches for investment are not offers to the public. Investments made in investee companies via funds managed by Sapphire Capital Partners LLP are not covered by the Financial Services Compensation Scheme (FSCS). For more details, please contact us or refer to their website: https://www.fscs.org.uk |